Development of 3D-QSAR models for 5-lipoxygenase antagonists: chalcones.

5-Lipoxygenase inhibitors are of current interest for asthma therapy and inflammatory diseases. In order to identify the essential structural and physicochemical requirements in terms of common biophoric sites (pharmacophore) and secondary sites for binding and interacting with 5-lipoxygenase, a series of 51 compounds of chalcones has been used for the development of 3D-QSAR models on APEX-3D expert system. Among several models, the two models have been identified with the statistical criteria R(2)>0.75, Chance <0.001 and Match >0.7. Both the models (nos 1 and 2) with three biophoric sites and four secondary sites, showed very good correlation (r>0.9) between the observed and calculated or predicted activities.

[1]  Michael R. Greenberg,et al.  Chapter 1 – Theory, Methods, and Applications , 1978 .

[2]  J. Rokach.  Leukotrienes and lipoxygenases , 1989 .

[3]  Y. Martin,et al.  Quantitative structure-activity relationships of 5-lipoxygenase inhibitors. Inhibitory potency of pyridazinone analogues. , 1994, Journal of pharmaceutical sciences.

[4]  S. Kc,et al.  Depsides as non-redox inhibitors of leukotriene B4 biosynthesis and HaCaT cell growth. 1. Novel analogues of barbatic and diffractaic acid , 1999 .

[5]  M. Edwards,et al.  Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. , 1991, Journal of medicinal chemistry.

[6]  R. D. Dyer,et al.  Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. , 1990, Journal of medicinal chemistry.

[7]  M. J. D. Powell,et al.  Restart procedures for the conjugate gradient method , 1977, Math. Program..

[8]  P. Young,et al.  5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones. , 1996, Journal of medicinal chemistry.

[9]  P. Tuchinda,et al.  Anti-inflammatory cyclohexenyl chalcone derivatives in Boesenbergia pandurata. , 2002, Phytochemistry.

[10]  Gordon M. Crippen,et al.  Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions , 1987, J. Chem. Inf. Comput. Sci..

[11]  R. Young.  Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized? , 1999 .

[12]  Renzi Pm.  Antileukotriene agents in asthma: The dart that kills the elephant? , 1999 .

[13]  H. Ueda,et al.  3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors. , 1993, Journal of medicinal chemistry.

[14]  B. Samuelsson,et al.  The inhibitory effects of BW 755C on arachidonic acid metabolism in human polymorphonuclear leukocytes , 1980, FEBS letters.

[15]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[16]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[17]  J. Petraitis,et al.  2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity. , 1990, Journal of medicinal chemistry.

[18]  H. Degreef,et al.  A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor. , 1990, Journal of the American Academy of Dermatology.